LGD 4033 is a synthetic cannabinoid developed by GW Pharmaceuticals and marketed under the trade name Sativex®. It was approved for medical use in June 2010 in the United Kingdom to treat symptoms associated with Multiple sclerosis spasticity and later expanded to include Dravet syndrome. It contains equal proportions of cannabidiol (CBD), which does not produce psychoactive effects, and tetrahydrocannabinol (THC), the primary psychoactive constituent of the marijuana plant. LGD-4033 results are best on men’s fitness.
Advantages of LGD 4033
The following advantages have been identified thus far:
This product is applied directly onto the skin and absorbed through the mouth, nose, and eyes mucous membranes. Many patients prefer this application method due to its ease of use and lack of side effects compared to smoking or eating cannabis products.
Due to the low levels of THC in the product, inhaling the smoke generated from burning LGD4033 is virtually non-existent. Therefore, the product’s therapeutic effect is felt almost exclusively via the topical route. However, the potential exists for some users to alter their behavior to obtain an elevated level of intoxication through the inhaled route.
Stimulation of appetite
Patients who suffer from weight loss often experience nausea and reduced appetite. Preliminary evidence suggests that LGD4033 may promote satiety and reduce human food intake.
Many patients find smoking cannabis to be physically unpleasant. The sensory aspects of smoking cannabis appear to provoke adverse emotional reactions in some people. By contrast, ingesting LGD4033 gives the patient much greater control over the onset and duration of drug action than taking orally administered cannabinoids such as THC.